InSightec's ExAblate(R) 2000 Receives Frost & Sullivan's Technology Innovation Award

    HAIFA, Israel, September 26 /PRNewswire/ -- InSightec's ExAblate(R) 2000,
 the first U.S. Food and Drug Administration (FDA) approved Magnetic
 Resonance-guided Focused Ultrasound (MRgFUS) technology for the non-invasive
 treatment of uterine fibroids has once again been recognized for technology
 achievement, the company said today. Frost & Sullivan, the international
 growth consultant, has awarded InSightec its 2005 Technical Innovation Award
 in the field of non-invasive medical devices for outstanding industry
 achievement.
     Frost & Sullivan's gives the Technology Innovation award to a company
 that has carried out new research that has resulted in innovation expected to
 bring significant contributions to its industry in terms of adoption, change,
 and competitive posture. This award recognizes the quality and depth of a
 company's research and development program as well as the vision a company
 had and the risks it took to undertake such an endeavor.
     "This is the fourth in a line of prestigious awards InSightec has
 received for the ExAblate 2000 technology," Dr. Jacob Vortman, president and
 CEO, InSightec said. "We are pleased by this, but more importantly, we are
 rewarded that so many women have already benefited from this patient-friendly
 solution for treating uterine fibroids and are investing in research on
 future applications that will enable other patients suffering from breast
 cancer, liver cancer, bone tumors, prostate cancer and brain tumors to be
 treated non-invasively for their tumors."
     In November 2004, The Wall Street Journal awarded the Company a Bronze
 Medal and Second Place in the Medical Category as part of its annual
 Technology Innovation Awards. Out of 585 applicants, the Journal picked the
 novel ideas that best addressed big challenges and had a wide-reaching
 impact. Rigorous data had to support the winners' real-world performance.
     Also in 2004, the European Information Society Technology awarded
 InSightec the IST Grand Prize, the most distinguished European Prize for
 innovative products and services in the field of information society
 technology. The award is given based on technical excellence, innovative
 content, potential market value, and the capacity to generate new jobs. Most
 recently, the ExAblate 2000 was also recognized by Advanced Imaging in its
 2005 Solutions of the Year issue.
     The ExAblate 2000 uses magnetic resonance imaging (MRI) in conjunction
 with highly-focused ultrasound to thermally ablate (destroy) tumors in the
 body. The unique MR thermometry feedback, provided by the system, allows the
 physician to monitor and control the treatment to ensure that the targeted
 tumor is fully treated and the healthy tissue is avoided. The ExAblate 2000
 is compatible only with GE Healthcare's SIGNA Magnetic Resonance systems.
     The system is currently in use at centers around the world for the
 treatment of uterine fibroids and clinical research trials are underway for
 potential applications in the treatment of both benign and cancerous tumors.
     For more information about the ExAblate(R) 2000 or InSightec, please
 visit www.insightec.com.
     About InSightec
     InSightec Image Guided Treatment Ltd. is a privately held company owned
 by Elbit Medical Imaging (EMI), General Electric, private investors and
 employees. It was founded in 1999 to develop the breakthrough MR guided
 Focused Ultrasound technology and transform it into the next generation
 operating room. Headquartered near Haifa, Israel, the company has over 100
 employees and has invested more than $80 million in research, development,
 and clinical investigations. Its U.S. headquarters are located in Dallas,
 Texas. For more information, please go to: http://www.insightec.com/
 
     Contact Information
 
     InSightec
     www.insightec.com
 
     Tel: +972-4-813-1329
     Email: info@insightec.com
 
     For media inquiries, contact:
 
     Fern Lazar
     Lazar Partners, Ltd.
     Tel: +1-(212)-867-1762
     Email: flazar@lazarpartners.com
 
     For more information, please visit http://www.uterine-fibroids.org
 
 
 
 

SOURCE  Insightec Ltd.